Adjuvant therapy
Real-World Evidence From FLEX: Utility of MammaPrint in Guiding Treatment Planning for Patients Aged 70 and Older With Early-Stage Breast Cancer
Publication: ASCO® 2025 Authors: Reshma Mahtani, Ana Sandoval-Leon, Anna Read More
Survival Outcomes for Patients With Invasive Lobular Cancer by MammaPrint: Results From the MINDACT Phase III Trial
Publication: European Journal of Cancer 217 (2025) 115222 Authors: Read More
Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky*, Read More
Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky, VK Read More
70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up study
Title: 70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage Read More
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients
Publication: Heliyon 10 (2024) e39485 Authors: Daniele Generali, Andrea Read More
MammaPrint Genomic Assay Providing Prognostic Information in Early Breast Cancer: 10-Year Follow-Up From a Retrospective German Breast Cancer Registry Analysis
Publication: EMJ Oncol. 2024;12[1]:138-147. Authors: C. Jackisch, D. Pronin, Read More
MammaPrint 3-year outcomes with CT with/without anthracycline
ASCO 2024, #511 Presenter: O'Shaughnessy et al.
Read MorePrediction of chemotherapy benefit by MammaPrint®, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 29 Authors: Audeh et al.
Read MoreAPHINITY (BIG 4-11) Trial: BluePrint prediction of CT Benefit w/ HER2-positive
APHINITY Trial (BIG 4-11) Authors: Krop, Piccart, et al
Read More
